Skip to content
Open access

Prognostic Value of Baseline High-Uptake PSMA Tumor Volume Fraction in Metastatic Castration-Resistant Prostate Cancer Patients Treated with [177Lu]Lu-PSMA Radioligand Therapy

Oct 2026 · Cancers · Vol 18 · 0 citations · 42 references
Medicine

Abstract

Simple Summary Lutetium-177 prostate-specific membrane antigen radioligand therapy is an effective option for metastatic castration-resistant prostate cancer, yet a substantial proportion of patients progress early and no validated PSMA-PET/CT biomarker is available to identify them before treatment. In 63 patients, we assessed semiquantitative baseline PSMA-PET/CT parameters describing the extent and distribution of PSMA-avid tumor burden, focusing on the proportion of total PSMA-positive tumor volume with uptake above a fixed SUV threshold of 20 (tPSMA-TV%). Higher baseline tPSMA-TV% was associated with lower odds of early biochemical progression and higher odds of PSA50 response and with longer PSA progression-free survival and overall survival; an exploratory cut-off of 47.54% discriminated early biochemical progression with high specificity but requires external validation. Because tPSMA-TV% is derived from the pretherapeutic scan already acquired in routine practice, it could contribute to baseline risk stratification before the first cycle, identifying patients at higher risk of early failure who may require closer monitoring.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.